ArticleClinical rheumatology2026
Antinuclear antibody titre and its dynamics predict autoimmune disease progression in adults with immune thrombocytopenia.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAntinuclear antibody (ANA) is frequently detected in patients with primary immune thrombocytopenia (ITP), but its prognostic value for subsequent autoimmune disease (AID) development remains unclear. This study aimed to evaluate the association between baseline ANA titre, its longitudinal dynamics and disease outcomes in adults with primary ITP.
methodsWe conducted a single-centre retrospective cohort study of 261 adults with primary ITP. ANA was tested at baseline and during follow-up. Generalised estimating equation (GEE) models and Cox regression were used to assess the associations between ANA titre and platelet counts, and between ANA titre and AID development.
resultsOver a median follow-up of 15 months, 23.75% had baseline ANA > 1:100. Higher ANA titres were significantly associated with lower platelet counts (global p = 0.002), particularly in 1:160 and 1:320 subgroups. Patients with ANA > 1:100 had significantly lower AID-free survival than those with ≤ 1:100 (log-rank p = 0.014). Dynamic ANA changes further stratified AID risk: rising (HR 7.159), persistently high (HR 3.515) and falling ANA (HR 3.598) all predicted higher risk versus consistently negative ANA (p = 0.035).
conclusionsBaseline ANA titre predicts lower platelet counts and higher AID risk in primary ITP. Serial ANA monitoring provides additional prognostic value, with rising or persistently high titres identifying patients at highest risk. ANA testing may aid in risk stratification and early AID detection. Key Points • Baseline ANA titre is significantly associated with lower platelet counts and higher risk of subsequent autoimmune disease in primary ITP. • Serial ANA monitoring provides additional prognostic value, with rising or persistently high titres identifying patients at greatest risk of autoimmune disease progression. • Dynamic changes in ANA titre (rising, persistent, or falling) all predict higher autoimmune disease risk compared with consistently negative ANA. • ANA testing and serial monitoring may facilitate risk stratification and early detection of autoimmune disease in patients with primary ITP.
Indexed as
Identifiers
42603197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.